Free Trial

Aligos Therapeutics (ALGS) Insider Trading & Ownership

Aligos Therapeutics logo
$18.59 +0.39 (+2.14%)
(As of 09:15 AM ET)

Aligos Therapeutics (NASDAQ:ALGS) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
8.75%
Number Of
Insiders Buying
(Last 3 Years)
1
Amount Of
Insider Buying
(Last 3 Years)
$6.03 M
Number Of
Insiders Selling
(Last 3 Years)
0
Get ALGS Insider Trade Alerts

Want to know when executives and insiders are buying or selling Aligos Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ALGS Insider Buying and Selling by Quarter

Aligos Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/25/2023Carole NuechterleinDirectorBuy317,344$19.00$6,029,536.00  
(Data available from 1/1/2013 forward)

ALGS Insider Trading Activity - Frequently Asked Questions

The list of insiders at Aligos Therapeutics includes Carole Nuechterlein. Learn more on insiders at ALGS.

8.75% of Aligos Therapeutics stock is owned by insiders. Learn more on ALGS's insider holdings.

The following insider purchased ALGS shares in the last 24 months: Carole Nuechterlein ($6,029,536.00).

Insiders have purchased a total of 317,344 ALGS shares in the last 24 months for a total of $6,029,536.00 bought.

Aligos Therapeutics Key Executives

  • Dr. Lawrence M. Blatt MBA (Age 62)
    Ph.D., CEO, President & Chairman of the Board
    Compensation: $1.03M
  • Dr. Julian A. Symons DPHIL (Age 62)
    Executive VP & Chief Scientific Officer
    Compensation: $735.51k
  • Dr. Matthew W. McClure M.D. (Age 52)
    Executive VP & Chief Medical Officer
    Compensation: $740.39k
  • Kristina Engeseth
    VP and Head of People & Culture
  • Dr. Sushmita M. Chanda DABT (Age 57)
    Ph.D., Executive Vice President & Chief Development Officer
  • Dr. David B. Smith Ph.D.
    Executive VP & Head of Chemical Operations
  • Dr. Tse-I Lin Ph.D.
    VP of Early Compound Development & Belgian Site Head


This page (NASDAQ:ALGS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners